Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study
- 46 Downloads
Testicular function of 17 males treated in childhood or adolescence for nephrotic syndrome (NS) with cyclophosphamide (CY) for a mean time of 240 days (mean total dosage of 16.4 g or 641 mg/kg body weight) was evaluated at a mean time of 11.8 years after treatment. Five were azoopsermic, 1 oligospermic, and 11 normospermic. There was a significant inverse correlation of sperm density with CY dosage and duration of treatment. All patients had undergone normal pubertal development and had normal sexual characteristics. Both basal and gonadotropin-releasing hormone-stimulated follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations were significantly raised in oligo- and azoospermic patients. Raised basal and peak FSH and LH concentrations in normospermic patients with a sperm count of less than 40×106/ml were in keeping with impairment of two testicular components. However, mean basal plasma testosterone levels and mean peak plasma testosterone responses to human chrionic gonadotropin (HCG) did not differ significantly between patients and controls. Although LH responses to gonadotropin-releasing hormone suggested compensated Leydig cell failure in patients with testicular tubular damage, secretory reserve capacity of these cells, estimated by a HCG stimulation test, was preserved. Further follow-up is required to ascertain whether in these patients Leydig cell failure will develop with time.
Key wordsTesticular function Cyclophosphamide Childhood nephrotic syndrome
Unable to display preview. Download preview PDF.
- 1.Coldbeck JH (1963) Experience with alkylating agents in the treatment of childhood nephrotic syndrome. Med J Aust 1: 987–989Google Scholar
- 2.Barratt TM, Soothill JF (1970) Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet II: 479–482Google Scholar
- 4.Fairley KF, Barrie JU, Johnson W (1972) Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet I: 568–569Google Scholar
- 5.Rapola J, Koskimies O, Huttunen NP, Floman P, Vilska J, Hallman N (1973) Cyclophosphamide and the pubertal testis. Lancet I: 98–99Google Scholar
- 11.Greifer I, Barnett HL (1972) International workshop on risk/benefit assessment of cyclophosphamide in renal disease. Kidney Int 2: 352–353Google Scholar
- 12.Trompeter RS, Evans PR, Barratt TM (1981) Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods. Lancet I: 1177–1179Google Scholar
- 13.Watson AR, Rance CP, Bain J (1985) Long-term effects of cyclophosphamide on testicular function. Br Med J 291: 1457–1460Google Scholar
- 14.WHO laboratory manual for the examination of human semen and semen-cervical mucus interactions (1980) WHO Press Concern, SingaporeGoogle Scholar
- 15.Arbeitsgemeinschaft für Pädiatrische Nephrologie (1982) Effects of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 306: 451–454Google Scholar
- 16.Buchanan JD, Fairley KF, Barrie JU (1975) Return of spermatogenesis after stopping cyclophosphamide therapy. Lancet II: 156–157Google Scholar
- 17.Rosen SW, Weintraub BD (1971) Monotropic increase of serum FSH correlated with low sperm count in young men with idiopathic oligospermia and aspermia. J Clin Endocrinol 32: 410–415Google Scholar